Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.62 |
| ▸ | NT5E | P21589 | 11/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19961902 | 0.80 | ADORA2A (0.55) | PDE2ANT5EADORA2A | |
| SCHEMBL19974427 | 0.75 | ADORA2A (0.68) | PDE2ANT5EADORA2A | |
| SCHEMBL19987256 | 0.72 | ADORA2A (0.61) | PDE2ANT5EADORA2A | |
| SCHEMBL19974361 | 0.72 | ADORA2A (0.61) | PDE2ANT5EADORA2A | |
| SCHEMBL19974455 | 0.71 | PDE2A (0.53) | PDE2ANT5EADORA2A | |
| SCHEMBL22700147 | 0.71 | PDE2A (0.53) | PDE2ANT5EADORA2A | |
| SCHEMBL19974417 | 0.71 | PDE2A (0.51) | PDE2ANT5EADORA2A | |
| SCHEMBL22700332 | 0.71 | PDE2A (0.57) | PDE2ANT5EADORA2A | |
| SCHEMBL19974448 | 0.70 | ADORA2A (0.55) | PDE2ANT5EADORA2A | |
| SCHEMBL23743767 | 0.69 | PDE2A (0.81) | PDE2ANT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
| US-10472364-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2018119284-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180072742-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072742-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | PDE2A 175/4885NT5E 1/4885ADORA2A 27/4885 |
| US-10472364-B2 | Ectonucleotidase inhibitors and methods of use thereof | ENTPD5, NT5E, ENTPD1 | PDE2A 274/4885NT5E 2/4885ADORA2A 11/4885 |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | PDE2A 175/4885NT5E 1/4885ADORA2A 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.